WRF
IONS icon

Waddell & Reed Financial’s Ionis Pharmaceuticals IONS Stock Holding History

Waddell & Reed Financial’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		$72.6M Sell
1,613,947
-536,823
-25% -$29.9M 0.15% 178
2020
Q4 		$122M Hold
2,150,770
– – 0.26% 109
2020
Q3 		$102M Sell
2,150,770
-15,555
-0.7% -$864K 0.24% 113
2020
Q2 		$128M Buy
2,166,325
+14
+0% +$779 0.33% 81
2020
Q1 		$102M Sell
2,166,311
-23,826
-1% -$1.33M 0.33% 83
2019
Q4 		$132M Sell
2,190,137
-989,941
-31% -$59M 0.33% 83
2019
Q3 		$191M Buy
3,180,078
+19
+0% +$1.24K 0.49% 48
2019
Q2 		$204M Sell
3,180,059
-182,247
-5% -$12.9M 0.51% 43
2019
Q1 		$273M Sell
3,362,306
-135,756
-4% -$8.76M 0.68% 33
2018
Q4 		$189M Sell
3,498,062
-334,649
-9% -$17.1M 0.54% 43
2018
Q3 		$198M Sell
3,832,711
-697,389
-15% -$32.8M 0.44% 56
2018
Q2 		$189M Hold
4,530,100
– – 0.44% 56
2018
Q1 		$200M Hold
4,530,100
– – 0.45% 57
2017
Q4 		$228M Sell
4,530,100
-12,000
-0.3% -$658K 0.51% 49
2017
Q3 		$230M Sell
4,542,100
-598,100
-12% -$31.3M 0.51% 52
2017
Q2 		$261M Sell
5,140,200
-10,400
-0.2% -$484K 0.58% 44
2017
Q1 		$207M Sell
5,150,600
-592,200
-10% -$26.6M 0.44% 66
2016
Q4 		$275M Sell
5,742,800
-70,600
-1% -$2.79M 0.6% 45
2016
Q3 		$213M Sell
5,813,400
-135,800
-2% -$4.25M 0.44% 63
2016
Q2 		$139M Buy
5,949,200
+148,100
+3% +$4.78M 0.29% 94
2016
Q1 		$235M Buy
5,801,100
+30,800
+0.5% +$1.25M 0.44% 65
2015
Q4 		$357M Hold
5,770,300
– – 0.58% 51
2015
Q3 		$233M Buy
5,770,300
+1,000
+0% +$51.8K 0.38% 71
2015
Q2 		$332M Buy
5,769,300
+318,900
+6% +$20.3M 0.47% 66
2015
Q1 		$347M Hold
5,450,400
– – 0.48% 62
2014
Q4 		$337M Sell
5,450,400
-43,700
-0.8% -$2.16M 0.47% 65
2014
Q3 		$213M Buy
5,494,100
+130,300
+2% +$4.62M 0.3% 90
2014
Q2 		$185M Buy
5,363,800
+48,900
+0.9% +$1.54M 0.27% 98
2014
Q1 		$230M Buy
5,314,900
+574,300
+12% +$27.8M 0.35% 77
2013
Q4 		$189M Buy
4,740,600
+506,200
+12% +$18M 0.3% 90
2013
Q3 		$159M Buy
4,234,400
+357,100
+9% +$10.7M 0.3% 89
2013
Q2 		$104M Buy
+3,877,300
New +$82.4M 0.22% 113

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Waddell & Reed Financial's IONS Position: Q1 2021 in Review

Waddell & Reed Financial reduced its Ionis Pharmaceuticals (IONS) stake by 25% in Q1 2021, selling an estimated $29.9M and leaving 1,613,947 shares worth $72.6M. The position accounts for 0.15% of the portfolio, ranked #178.

Waddell & Reed Financial first reported a position in IONS in Q2 2013 and has held it in 32 quarters since. The position peaked at $357M in Q4 2015. 365 funds tracked by Wall St. Rank hold IONS as of Q1 2021.

  • Waddell & Reed Financial held 1,613,947 shares of Ionis Pharmaceuticals worth $72.6M as of Q1 2021.
  • Waddell & Reed Financial sold 536,823 Ionis Pharmaceuticals shares in Q1 2021, an estimated $29.9M.
  • Ionis Pharmaceuticals made up 0.15% of Waddell & Reed Financial's portfolio in Q1 2021, its #178 holding.
  • Waddell & Reed Financial first reported a position in Ionis Pharmaceuticals in Q2 2013 and has held it in 32 quarters since.
  • Waddell & Reed Financial's Ionis Pharmaceuticals position peaked at $357M in Q4 2015.
  • 365 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2021.

Based on Waddell & Reed Financial's 13F filing for Q1 2021, filed 12 May 2021.